Metformin delayed release - Elcelyx Therapeutics

Drug Profile

Metformin delayed release - Elcelyx Therapeutics

Alternative Names: EFB0027; Met DR; NewMet

Latest Information Update: 06 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elcelyx Therapeutics
  • Class Antihyperglycaemics; Biguanides; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 10 Nov 2016 Positive safety and efficacy results from a phase IIb trial in Type-2 diabetes mellitus released by Elcelyx Therapeutics
  • 01 Sep 2016 Elcelyx Therapeutics completes a phase IIb trial in Type-2 diabetes mellitus in USA and Puerto Rico (NCT02526524)
  • 25 May 2016 Elcelyx Therapeutics completes enrolment in its phase IIb trial for Type-2 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top